Who is eligible for clinical trial NCT07753993?

Participants must meet the protocol's inclusion criteria for Chronic Kidney Disease. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07753993 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-04

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. (NCT07753993)

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)

🟡 Not Yet Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (10 items).

Location: Research Site — Sheffield, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges.
On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
BMI \<23 kg/m² at screening
History of type 1 diabetes mellitus
HbA1c ≥10% (86 mmol/mol) at screening
Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.
Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness
Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening
Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
History/family history (first degree) of medullary thyroid cancer or MEN2

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (426 Sites)

Showing the first 25 of 426 sites.

Research Site — Sheffield, Alabama
Research Site — Surprise, Arizona
Research Site — Chula Vista, California
Research Site — Waterbury, Connecticut
Research Site — Chicago, Illinois
Research Site — Topeka, Kansas
Research Site — Beltsville, Maryland
Research Site — Boston, Massachusetts
Research Site — Troy, Michigan
Research Site — Edina, Minnesota
Research Site — Saint Paul, Minnesota
Research Site — Eatontown, New Jersey
Research Site — Albany, New York
Research Site — Buffalo, New York
Research Site — Mineola, New York
Research Site — Morehead City, North Carolina
Research Site — Shelby, North Carolina
Research Site — Statesville, North Carolina
Research Site — Wilmington, North Carolina
Research Site — Wilmington, North Carolina
Research Site — Maumee, Ohio
Research Site — Rapid City, South Dakota
Research Site — Knoxville, Tennessee
Research Site — Morristown, Tennessee
Research Site — Arlington, Texas

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Kidney Disease

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease — San Dimas, California
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease — Miami, Florida
Trial to Evaluate and Assess the Effect of Comprehensive Pre-ESKD Education on Home Dialysis Use in Veterans — Gainesville, Florida
Chronic Kidney Disease in Children Prospective Cohort Study (CKiD) — Kansas City, Missouri
Renal Impairment Study for Oral EC5026 — Sacramento, California
Patient-driven Management of BP in CKD — Iowa City, Iowa

Explore by condition: All Chronic Kidney Disease clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗